Stryker Corporation $SYK Holdings Raised by Howe & Rusling Inc.

Howe & Rusling Inc. increased its stake in Stryker Corporation (NYSE:SYK) by 2.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,321 shares of the medical technology company’s stock after purchasing an additional 643 shares during the quarter. Stryker comprises about 0.9% of Howe & Rusling Inc.’s portfolio, making the stock its 28th biggest holding. Howe & Rusling Inc.’s holdings in Stryker were worth $12,392,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of SYK. United Services Automobile Association bought a new stake in shares of Stryker in the 1st quarter worth $2,857,000. Hendley & Co. Inc. grew its holdings in Stryker by 60.3% during the second quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company’s stock worth $5,546,000 after acquiring an additional 5,274 shares during the period. AXS Investments LLC raised its position in Stryker by 13.7% in the first quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock worth $3,286,000 after acquiring an additional 1,062 shares in the last quarter. Two Point Capital Management Inc. bought a new stake in Stryker in the second quarter worth about $7,281,000. Finally, King Luther Capital Management Corp lifted its holdings in Stryker by 7.9% in the 2nd quarter. King Luther Capital Management Corp now owns 447,479 shares of the medical technology company’s stock valued at $177,036,000 after acquiring an additional 32,682 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. This represents a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 522,453 shares of company stock valued at $185,516,867. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Up 1.4%

NYSE SYK opened at $364.39 on Thursday. The firm’s 50 day moving average price is $370.25 and its two-hundred day moving average price is $380.91. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The stock has a market cap of $139.35 billion, a price-to-earnings ratio of 48.26, a PEG ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the prior year, the company earned $2.87 earnings per share. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on SYK shares. Evercore ISI lowered their price objective on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Rothschild Redb raised Stryker to a “hold” rating in a report on Thursday, September 18th. BTIG Research reiterated a “buy” rating and set a $410.00 price objective on shares of Stryker in a research report on Friday, November 14th. Finally, UBS Group set a $408.00 target price on Stryker in a report on Monday, October 13th. Thirteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $434.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.